Telix Pharmaceuticals said Part 1 of its global Phase 3 ProstACT study achieved its primary objectives, reporting an acceptable safety and tolerability profile for its investigational therapy TLX591-Tx in patients with advanced prostate cancer. The company indicated these findings support moving the program into the next stage, a larger randomized expansion comparing TLX591-Tx given with standard-of-care therapies against standard treatments alone.
Following the announcement, shares of the Australia-based biopharmaceutical firm climbed sharply in Sydney trading. The stock rose as much as 14% to A$11.62 and was last noted trading 8% higher at A$11.0 by 01:20 GMT.
TLX591-Tx is a targeted radiopharmaceutical developed to treat prostate-specific membrane antigen, or PSMA-positive, metastatic castration-resistant prostate cancer. In the ProstACT Part 1 cohort, the candidate was tested in combination with commonly used standard therapies, including enzalutamide, abiraterone and docetaxel. Telix characterized the safety and tolerability outcomes as acceptable for the enrolled population.
On the basis of the Part 1 data, Telix said it intends to advance the study into a randomized expansion that will directly compare the drug administered alongside standard-of-care therapies to standard treatment alone. The company also plans to present the Part 1 results to the U.S. Food and Drug Administration as it seeks to progress the trial in the United States.
The Part 1 readout addresses an early-stage regulatory and clinical milestone: establishing a safety and tolerability profile sufficient to justify broader testing in a randomized setting. Telix described the outcome as meeting the primary objectives set for this initial portion of the global Phase 3 ProstACT program.
Investors reacted to the announcement with a meaningful intraday move in the shares, reflecting market attention to clinical progress and regulatory planning for oncology candidates in development.
Key points
- Part 1 of the global Phase 3 ProstACT study met its primary objectives, showing acceptable safety and tolerability for TLX591-Tx in advanced prostate cancer patients - sectors impacted: Biotechnology, Healthcare.
- Telix plans a larger randomized expansion comparing TLX591-Tx plus standard therapies against standard treatment alone - sectors impacted: Clinical research, Pharmaceuticals.
- Shares reacted positively, rising as much as 14% intraday and last trading 8% higher at A$11.0 by 01:20 GMT - sectors impacted: Equity markets, Healthcare investing.
Risks and uncertainties
- Further clinical stages remain — the Part 1 outcome is supportive but the program must still advance through a larger randomized expansion before broader efficacy conclusions can be drawn - sectors impacted: Clinical research, Pharmaceuticals.
- Regulatory review and approval processes are ongoing considerations — Telix plans to present data to the U.S. Food and Drug Administration, and progress in the United States is not guaranteed - sectors impacted: Regulatory affairs, Healthcare markets.